Adverse drug reactions in herding-breed dogs: The role of P-glycoprotein

Compendium on Continuing Education for the Practicing Veterinarian

Volumn 28, Issue 1, 2006, Pages 23-33

  Mealey, Katrina L ^a  

^a WASHINGTON STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANIS FAMILIARIS;

EID: 32844470268     PISSN: 01931903     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (62)

1. Mealey KL, Bentjen SA, GayJM, Cantor GH: Ivermectin sensitivity in collies is associated with a deletion mutation of the mdr1 gene. Pharmacogenetics 11:727-733, 2001.
2. Nelson OL, Carsten E, Bentjen SA, Mealey KL: Ivermectin toxicity in an Australian shepherd dog with the MDR1 mutation associated with ivermectin sensitivity in collies. J Vet Intern Med 17:354-356, 2003.
3. Ueda K, Cardarelli C, Gottesman MM, Pastan I: Expression of a full-length cDNA for the human MDR1 gene confers resistance to colchicine, doxorubicin, and vinblastine. Proc Natl Acad Sci USA:3004-3008, 1987.
4. Juranka PF, Zastawny RL, Ling V: P-glycoprotein: Multidrug-resistance and a superfamily of membrane-associated transport proteins. FASEB J 3:2583-2592, 1989.
5. Bergman PJ, Ogilvie GK, Powers BE: Monoclonal antibody C219 immuno-histochemistry against P-glycoprotein: Sequential analysis and predictive ability in dogs with lymphoma. J Vet Intern Med 10:354-359, 1996.
6. Mealey KL, Barhoumi R, Rogers K, Kochevar DT: Doxorubicin induced expression of P-glycoprotein in a canine osteosarcoma cell line. Cancer Lett 126, 187-192, 1998.
7. Cornwell MM: Molecular biology of P-glycoprotein. Cancer Treat Res 57:37-56, 1991.
8. Li M, Hurren R, Zastawny RL, et al: Regulation and expression of multidrug resistance (MDR) transcripts in the intestinal epithelium. Br J Cancer 80:1123-1131, 1999.
9. Cordon-Cardo C, O'Brien JP, Casals D, et al: Multidrug-rcsistancc gene (P-glycoprotein) is expressed by endothelial cells at blood-hrain harrier sites. Proc Natl Acad Sci USA:695-698, 1989.
10. Thiebaut F, Tsuruo T, Hamnda H, et al: Cellular localization of the multidruprcsistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA:7735-7738, 1987.
11. Hori R, Okamura N, Aiba T, Tanigawara Y: Role of P-glycoprotein in renal tubular secretion of digoxin in the isolated perfused rat kidney. J Pharmacol Exp Ther 266:1620-1625,1993.
12. Lankas GR, Wise LD, Cartwright ME, et al: Placental P-glycoprotein deficiency enhances susceptibility to chemically induced birth defects in mice. Reprod Toxicol 12:457-463, 1998.
13. Melaine N, Lienard MO, Dorval I, et al: Multidrug resistance genes and P-glycoprotein in the testis of the rat, mouse, guinea pig, and human. Biol Reprod 67:1699-1707, 2002.
14. van Veen HW, Konings WN: The ABC family of multidrug transporters in microorganisms. Biochim Biophys Acta 1365:31-36, 1998.
15. Volkman SK, Cowman AK, Wirth DF: Functional complementation of the ste6 gene of Sacchanroyces cerevisiae with the pfmdr1 gene of Plasmodium faleiparum. Proc Natl Acad Sci USA:8921-8925, 1995.
16. Ramage G, Bachmann S, Patterson TF, et al: Investigation of multidrug efflux pumps in relation to fluconazole resistance in Candida albicans biofilms. J Antimicrob Chenmother 49:973-980, 2002.
17. Konings WN, Poclarends GJ: Bacterial multidrug resistance mediated by a homologue of the human multidrug transporter P-glycoprotcin. IUBMB Life 53:213-218, 2002.
18. Xu M, Molento M, Blackball W, et al: Ivermectin resistance in nematodes may be caused by alteration of P-glycoprotein homolog. Mol Biochem Parasitol 91:327-335, 1998.
19. Ford JM, Hait WN: Pharmacologic circumvention of multidrug resistance. Cytotechnology 12:171-212, 1993.
20. Sakaeda T, Nakamura T, Okumura K: MDR1 genotype-related pharmacokinetics and pharmaeodynamics. Biol Pharm Bull 25:1391-1400, 2002.
21. Seelig A: A general pattern for substrate recognition by P-glycoprotein. Eur J Biochem 251:252-261, 1998.
22. Marzolini C, Paus E, Buclin T, Kim RB: Polymorphisms in human MDR1 (P-glycoprotein): Recent advances and clinical relevance. Clin Pharmacol Ther 75:13-33, 2004.
23. Schwab M, Eichelbaum M, Fromm MF: Genetic polymorphisms of the human MDR1 drug transporter. Annu Rev Phamacol Toxicol 43:285-307, 2003.
24. Sakaeda T, Nakamura T, Okumura K: Pharmacogenetics of MDR1 and its impact on the pharmacokinetics and pharmaeodynamics of drugs. Pharmacognnomics 4:397-410, 2003.
25. Page RL, Hughes CS, Huyan S, et al: Modulation of P-glycoprotein-mediated doxorubiein resistance in canine cell lines. Anticancer Res 20:3533-3538, 2000.
26. Okai Y, Nakamura N, Matsushiro H, et al: Molecular analysis of multidrug resistance in feline lymphoma cells. Am J Vet Res 61:1122-1127, 2000.
27. Schinkel AH, Smit JJ, van Tellingen O, et al: Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 20(77):491-502, 1994.
28. Schinkel AH, Wagenaar E, van Deemter L. et al: Absence of the mdr1a P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J Clin Invest 96:1698-1705, 1995.
29. Schinkel AH, Mol CA, Wagenaar E, et al: Multidrug resistance and the role of P-glycoprotein knockout mice. Eur J Cancer 31A:1295-1298, 1995.
30. Paul AJ, Tranquilli WJ, Seward RL, et al: Clinical observations in collies given ivermectin orally. Am J Vet Res 48:684-685, 1987.
31. Sparreboom A, van Asperen J, Mayer U, et al: Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc Nutl Acad Sci USA:2031-2035, 1997.
32. Lown KS, Mayo RR, Leichtman AB, et al: Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine. Clin Pharmacol Ther 62:248-260, 1997.
33. Schwarz UI, Gramatte T, Krappweis J, et al: Unexpected effect of verapamil on oral bioavailability of the beta-blocker talinolol in humans. Clin Pharmacol Ther 65:283-290, 1999.
34. Bouer R, Barthe L, Philibert C, et al: The roles of P-glycopro xin und intraccllular metabolism in the intestinal absorption of incthadone: In vitro studies using the rat everted intestinal sac. Fundam Clin Pharmacad 13:494-500, 1999.
35. Wandel C, Kim R, Wood M, Wood A: Interaction of morphine, fentanyl, sufentanil, alfentanil, and loperamide with the efflux drug transporter P-glyeoprotein. Anestbesiology 96:913-920, 2002.
36. Kwei GY, Alvaro RF, Chen Q, et al: Disposition of ivermectin and cyclosporin A in CF-1 mice deficient in mdr1a P-glycoprotein. Drug Metab Dispos 27:581-587, 1999.
37. Westphal K, Weinbrenner A, Giessmann T, et al: Oral bioavailability of digoxin is enhanced by talinolol: Evidence for involvement of intestinal P-glycoprotein. Clin Pharmacol Ther 68:6-12, 2000.
38. Yamuguchi H, Yano I, Saito H, Inui K: Pharmacokinetic role of P-glycoprotein in oral bioavailability and intestinal secretion of grepafloxacin in vivo. J Pharmacol Exp Ther 300:1063-1069, 2002.
39. McEntee M, Silverman JA, Rassnick K, et al: Enhanced bioavailability of oral docetaxel by coadministration of cyclosporin A in dogs and rats. Vet Lamp Onol 2:105-112, 2003.
40. Amatori FM, Meucci V, Giusiani M, et al: Effect of grapefruit juice on the pharmacokinetics of cyclosporine in dogs. Vet Rec 154:180-181, 2004.
41. Henick RA, Kellum HB, Bentjen SA, Mealey KL: Digoxin and mexiletine sensitivity in a collie with the mdr1 mutation. J Vet Intern Vet J, accepted for publication, 2005.
42. Boothe D: Small Animal Clinical Pharmacology and Therapeutics. Philadelphia, WB Saunders, 2001.
43. Sartor LL, Bentjen SA, Trepanier L, Mealey KL: Loperamide toxicity in a collie with the MDR1 mutation associated with ivcnncctin sensitivity. J Vet Intern Med 18:117-118, 2004.
44. Ericsson CD, Johnson PC: Safety and efficacy of loperamide. Am J Med 88:10S-14S, 1990.
45. Package insert: Revolution, Pfizer, 2005.
46. Tranquilli WJ, Paul AJ, Todd KS: Assessment of toxicosis induced by high-dose administration of milbemycin oxime in collies. Am J Vet Res 52:1170-1172,1991.
47. Patel J, Mitra AK: Strategies to overcome simultaneous P-glycoprotein mediated efflux and CYP3A4 mediated metabolism of drugs. Pharmacogenomics 2:401-415, 2001.
48. Zhang Y, Benet I.Z: The gut as a barrier to drug absorption: Combined role of cytochrome P450 3A and P-glycoprotein. Clin Pharmacokinet 40:159-168, 2001.
49. Dahlinger J, Gregory C, Bea J: Effect of ketoconazole on cyclosporine dose in healthy dogs. Vet Surg 27:64-68, 1998.
50. Patricelli AJ, Hardie RJ, McAnulty JE: Cyclosporinc and ketoconazole for the treatment of perianal fistulas in dogs. JAVMA 220:1009-1016, 2002.
51. Kiso S, Cai SH, Kitaichi K, et al: Inhibitory effect of crythromycin on P-glycoprotein-meduited biliary excretion of doxorubicin in rats. Anticanccr Res 20:2827-2834, 2000.
52. Mealey KL, Bentjen SA: Unpublished data, Veterinary Clinical Pharmacology Laboratory, Pullman, WA, 2005.
53. Mealey KL, Bentjen SA, Waiting DK: Frequency of the mutant MDR1 allele associated with ivermectin sensitivity in a sample population of collies from the northwestern United States. Am J Vet Res 63:479-481, 2002.
54. Neff MW, Rohertson KR, Wong AK, et al: Breed distribution and history of canine MDR1-1(Delta), a pharmatogenetic mutation that marks the emergence of breeds from the collie lineage. Proc Natl Acad Sci USA, 2004.
55. Hugnet C, Bentjen SA, Mealey KL: Frequency of the mutan: MDR1 allele associated with multidrug sensitivity in a sample of collies from France. J Vet Pharmacol Ther 27:227-229, 2004.
56. Mealey KL, Munyard KA, Bentjen SA: Frequency of the mutant MDR1 allele associated with multidrug sensitivity in a sample of herding breed dogs living in Australia. Vet Parasitol 131:193-196, 2005.
57. Mealcy KL, Northrup NC, Bentjen SA: Increased toxicity of P-glycoprotein-substrate chemotherapeutic agents in a dug with the MDR1 deletion mutation associated with ivermeetin sensitivity. JAVMA 223:1434, 1453-1455, 2003.
58. Frei E: Curative cancer chemotherapy. Cancer Res 45:6523-6537, 1985.
59. Fromm MF: Genetically determined differences in P-glycoprotein function: Implications for disease risk. Toxicology 181-182, 299-303, 2002.
60. Choo EF, Leake B, Wandel C, et al: Pharmacological inhibition of P-glyco protein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. Drug Metab Dispos 28:655-660, 2000.
61. Sadeque AJ, Wandel C, He H, et al: Increased drug delivery to the brain by P-glycoprotein inhibition. Clin Pbarmacol Ther 68:231-237, 2000.
62. Roulet A, Puel O, Gesta S, et al: MDR1 deficient genotype in collie dogs hypersensitive to the P-glycoprotein substrate ivermectin. Eur J Pharmacol 460:85-91, 2003.